The Woodlands, Texas, February 9, 2000 - Lexicon Genetics Incorporated today announced the filing of a registration statement with the Securities and Exchange Commission for a proposed initial public offering of its common stock. All of the shares to be registered will be offered by Lexicon. J.P. Morgan & Co. and Credit Suisse First Boston are co-lead managers of the offering, with J.P. Morgan & Co. acting as bookrunning lead manager. Dain Rauscher Wessels and Punk, Ziegel & Company are acting as co-managers. Copies of the prospectus, when available, may be obtained from J.P. Morgan & Co., 60 Wall Street, New York, New York 10260, Phone # 212/648-8612.
Lexicon is a leading genomics company using proprietary gene trapping technology to discover thousands of novel genes and expand its OmniBank® library of tens of thousands of knockout mouse clones for drug discovery. Lexicon's Internet exchange, Lexgen.com, enables researchers worldwide to access the OmniBank library and form collaborations with Lexicon to discover pharmaceutical products based on genes and knowledge of their functions.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This announcement shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state. |
